Regenerative Artificial Skin Market
Incidence of accidental skin burns are increasing across the globe. Life threatening skin injuries, traumas, and burns require immediate surgical procedure to restore skin and avoid future complications. Skin burns are broadly classified into three levels, namely 1st, 2nd, and 3rd degree burns. In third degree of burns where there is little or no intact skin, artificial skin graft is the most useful treatment option. Artificial skin covers and protects the wound and also promotes regeneration of natural skin.
Artificial skin is usually prepared from collagen, which is easily resorbed by the body and facilitates generation of new skin on the affected area. According to the American Burn Association, 486,000 people received medical treatment for minor burns and 70,000 people were hospitalized for severe skin burn requiring acute care in the U.S, in 2015. Various players in the market are carrying R&D activities to develop new technology related to artificial skin regeneration. One such instance is an autologous spray on skin, Recell, by Avita Medical.
Artificial Skin Treatments
Various skin repair devices are available, which are used to heal the affected part. These include Dermagraft, OrCel, Integra, Biobrane, Apligraft, Matriderm, Hyalomatrix, Renoskin, and Composite Cultured Skin. Dermagraft is used to help in wound closure of diabetic foot ulcers. Orcel is used to cover and aid in wound healing. Composite Cultured Skin also contains living cells and is specifically used in children with recessive dystrophic epidermolysis bullosa. Integra is used for treatment of severe burns.
Regenerative Artificial Skin Market Taxonomy
The global regenerative artificial skin market is segmented on the basis of material type, end user and region.
On the basis of material type, the regenerative artificial skin market is segmented into temporary skin material, permanent skin material, and composite skin material.
Temporary skin material: Its effect lasts between several months and 2.5 years, depending on the type, quality, and quantity of injected material.
Permanent skin material: These are epidermal skin and dermal skin materials. Bio-Alcamid is a synthetic polymer that contains 97% water. It is injected into the inner tissue to fill and thicken it.
Composite Skin Material: These are further sub-segmented into skin graft and engineered skin material.
On the basis of end user, the global regenerative artificial skin market is segmented into hospitals, clinics, and burn care center. In hospitals, regenerative artificial skin technology is used in the treatment of deep skin wounds and also in plastic surgery. Healthcare providers use artificial skin to treat chronic wounds. Specialized burn care center extensively use artificial skin technology to treat burnt skin.
Inadequate Medical Infrastructure and Low Access to Medical Facilities in Developing Economies a Major Restrain for Market Growth
The market for regenerative artificial skin is growing in the U.S., mainly driven by increasing number of patients with skin diseases. According to Skin Cancer Foundation, each year over 5.4 million cases of non-melanoma skin cancer are reported and over 3.3 million people are treated for the same in the U.S. Also, there are more new cases of skin cancer reported than the combined incidence of cancers of the breast, prostate, lung, and colon each year. Regenerative artificial skin market in Europe is growing due to skin disease being a very pertinent issue in the region. Robust medical infrastructure, presence of global players, and advancements in technology also contribute to market growth of the regenerative artificial skin in the region. In Asia, the market for regenerative artificial skin is projected to grow in the near future due to increasing number of people opting for skin treatment procedures.
Lack of Essential Sterile Environment Restricts Access to Regenerative Artificial Skin
Regenerative artificial skin market is expected to grow, with increasing incidence of burns. In addition, rising prevalence of skin diseases, growing number of harmful acid accidents, and increasing number of major body surgeries conducted is projected to positively impact regenerative artificial skin market in the near future. However, issues with acceptance by the recipient body and lack of sterile product and nutritional supply to regain the natural structure restricts growth of regenerative artificial skin market, especially in developing regions.
Rapid Advancements in Technology
Researchers and biotechnicians at the U.S army institute of surgical research are developing artificial skin that can be stored in a spray bottle and would regenerate and grow as applied on the body. This new technology would be of great aid in emergency situations, especially for military personnel during war situations. Furthermore, several companies in the market place are increasing their product portfolio related to regenerative artificial skin market. Some of the key players in the global regenerative artificial skin market are Integra Life Sciences Corporation, Mylan N.V., Johnson & Johnson Services, Inc. Smith & Nephew and Mallinckrodt plc.
Increasing research and development activities, as well as product innovations by market players are some of the key factors driving the market growth. For instance, in April 2019, South Korea-based T&R Biofab registered a patent for its 3D bioprinting technology to create artificial skin. The technology operates through the 3D printing of dermal and epidermal cells that uses a porous 3D structure to form skin with similar characteristics to actual tissue.
Moreover, strategic collaborations and partnerships among key market players are expected to facilitate growth of the regenerative artificial skin market. For instance, in June 2019, South Korea-based companies, T&R Biofab and SCM Life Science, announced plans to collaborate in the research and development of new 3D printed tissue regenerative products.
Strategic acquisitions and partnerships among key players are expected to drive the market growth. In May 2019, Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices entered an agreement to acquire Solsys Medical, LLC, and a regenerative medical company. The acquisition is expected to help Misonix to expand its portfolio with the addition of Solsys Medical’s wound care solutions.